Página principal > Resultados de la búsqueda: Dai, Sandra
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
13 p, 1.6 MB First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab : final analysis of the randomized, phase III iLLUMINATE trial / Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Greil, Richard (Salzburg Cancer Research Institute-CCCIT (Àustria)) ; Demirkan, Fatih (Dokuz Eylul University (Turquía)) ; Tedeschi, Alessandra (Niguarda Ca Granda Hospital (Itàlia)) ; Anz, Bertrand (Tennessee Oncology (Estats Units)) ; Larratt, Loree (University of Alberta Hospital (Canadà)) ; Simkovic, Martin (University Hospital and Medical School Hradec (Txèquia)) ; Novak, Jan (Charles University (Txèquia)) ; Strugov, Vladimir (Almazov National Medical Research Centre (Rússia)) ; Gill, Devinder (Princess Alexandra Hospital) ; Gribben, John G. (Barts Cancer Institute) ; Kwei, Kevin (Pharmacyclics LLC) ; Dai, Sandra (Pharmacyclics LLC) ; Hsu, Emily (Pharmacyclics LLC) ; Dean, James P. (Pharmacyclics LLC) ; Flinn, Ian W. (Sarah Cannon Research Institute) ; Universitat Autònoma de Barcelona
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. [...]
2022 - 10.3324/haematol.2021.279012
Haematologica, Vol. 107 (january 2022) , p. 2108-2120  
Registro completo - Creative Commons
2.
12 p, 1.8 MB Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study / Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ; Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ; Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ; Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ; Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ; Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ; Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ; Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ; McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ; Kipps, Thomas J. (UCSD Moores Cancer Center) ; Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798  
Registro completo - Creative Commons
3.
11 p, 1.8 MB Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma / Munir, Talha (St. James's Hospital ( Dublín, Irlanda)) ; Brown, J. R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; O'Brien, Susan (UC Irvine. Chao Family Comprehensive Cancer Center) ; Barrientos, Jacqueline C. (Northwell Health Cancer Institute (Estats Units d'Amèrica)) ; Barr, Paul M (Wilmot Cancer Institute. University of Rochester Medical Center) ; Reddy, N. M. (Vanderbilt-Ingram Cancer Center) ; Coutre, Steven E. (Stanford Cancer Center. Stanford University School of Medicine) ; Tam, C. S. (Peter MacCallum Cancer Centre. St. Vincent's Hospital and University of Melbourne) ; Mulligan, S. P. (Royal North Shore Hospital) ; Jaeger, Ulrich (Division of Hematology and Hemostaseology. Medical University of Vienna) ; Kipps, T. J. (UCSD Moores Cancer Center) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Montillo, M. (Niguarda Ca' Granda Hospital) ; Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Byrd, J. C. (The Ohio State University Comprehensive Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Dai, Sandra (Pharmacyclics LLC. an AbbVie Company) ; Szoke, A. (Pharmacyclics LLC. an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ; Woyach, J. A. (The Ohio State University Comprehensive Cancer Center) ; Universitat Autònoma de Barcelona
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [...]
2019 - 10.1002/ajh.25638
American Journal of Hematology, Vol. 94 Núm. 12 (january 2019) , p. 1353-1363  
Registro completo - Creative Commons

Vea también: autores con nombres similares
1 Dai, S.
1 Dai, Su-Juan
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos